SCYNEXIS Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de SCYNEXIS de 48.7% y 30.8% respectivamente, mientras que el BPA crecerá en un 49.2% al año.

Información clave

48.7%

Tasa de crecimiento de los beneficios

49.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.7%
Tasa de crecimiento de los ingresos	30.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	07 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12

Recent updates

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 08

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:SCYX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	111	65	17	40	4
12/31/2025	53	8	N/A	12	4
12/31/2024	10	-22	N/A	-14	4
9/30/2024	9	-36	-22	-22	N/A
6/30/2024	10	-35	-10	-10	N/A
3/31/2024	140	101	75	75	N/A
12/31/2023	140	67	60	60	N/A
9/30/2023	136	72	45	45	N/A
6/30/2023	136	44	10	10	N/A
3/31/2023	6	-91	-83	-83	N/A
12/31/2022	5	-63	-80	-80	N/A
9/30/2022	4	-78	-83	-83	N/A
6/30/2022	3	-49	-78	-77	N/A
3/31/2022	2	-34	-71	-70	N/A
12/31/2021	13	-33	-56	-55	N/A
9/30/2021	13	-46	-46	-46	N/A
6/30/2021	12	-45	-39	-39	N/A
3/31/2021	12	-53	-36	-36	N/A
12/31/2020	N/A	-55	-49	-49	N/A
9/30/2020	N/A	-27	-46	-46	N/A
6/30/2020	N/A	-36	-47	-47	N/A
3/31/2020	0	-38	-46	-46	N/A
12/31/2019	0	-54	-38	-38	N/A
9/30/2019	0	-37	-31	-31	N/A
6/30/2019	0	-29	-27	-26	N/A
3/31/2019	0	-31	-27	-27	N/A
12/31/2018	0	-12	-29	-28	N/A
9/30/2018	0	-22	-28	-27	N/A
6/30/2018	0	-31	N/A	-27	N/A
3/31/2018	0	-24	N/A	-26	N/A
12/31/2017	0	-25	N/A	-25	N/A
9/30/2017	0	-21	N/A	-24	N/A
6/30/2017	0	-24	N/A	-26	N/A
3/31/2017	0	-28	N/A	-27	N/A
12/31/2016	0	-30	N/A	-29	N/A
9/30/2016	0	-35	N/A	-31	N/A
6/30/2016	0	-31	N/A	-30	N/A
3/31/2016	0	-30	N/A	-29	N/A
12/31/2015	0	-28	N/A	-25	N/A
9/30/2015	1	-23	N/A	-20	N/A
6/30/2015	1	-19	N/A	-18	N/A
3/31/2015	1	-11	N/A	-14	N/A
12/31/2014	1	-7	N/A	-9	N/A
9/30/2014	4	-42	N/A	-9	N/A
6/30/2014	8	-43	N/A	-6	N/A
3/31/2014	12	-47	N/A	-2	N/A
12/31/2013	17	-47	N/A	-4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que SCYX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que SCYX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que SCYX sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (30.8% al año) de SCYX crezcan más rápidamente que los del mercado US (9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (30.8% al año) de SCYX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SCYX se prevé que sea elevada dentro de 3 años.

SCYNEXIS Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Consensus estimates of losses per share improve by 12%

Consensus revenue estimates fall by 59%

Price target decreased by 12% to US$7.13

Price target decreased by 9.6% to US$10.30

Price target increased by 7.5% to US$11.40

Recent updates

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024

Consensus estimates of losses per share improve by 12%

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Consensus revenue estimates fall by 59%

Scynexis: Update Following Restructuring Of GSK Deal

Full year 2023 earnings: EPS and revenues miss analyst expectations

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Bronstein, Gewirtz & Grossman LLC Announces SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Price target decreased by 12% to US$7.13

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology

SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance

Price target decreased by 9.6% to US$10.30

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.5% to US$11.40

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Consensus revenue estimates fall by 35%

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$15.00

SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health

SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022

SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

SCYNEXIS, Inc. Announces CEO Changes

SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$18.17

SCYNEXIS Q2 2022 Earnings Preview

SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update

SCYNEXIS gains after favorable data for antifungal agent in new indication

Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

Consensus forecasts updated

Price target decreased to US$21.25

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022

No longer forecast to breakeven

Insufficient new directors

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million.

SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Consensus revenue estimates fall by 30%